In today’s briefing:
- Odyssey Therapeutics, Inc.(ODTX): Biotech Combating Ulcerative Colitis, or UC, Files for IPO
- ACHV: Long-Term Exposure Requirement Complete
- CCLD: Initiating Coverage of a Differentiated Technology-Led Business Solutions Provider Focused on the Healthcare Industry
- EVAX: Share Ratio Adjustment
- SCLX: 3Q Earnings Beat Estimates
Odyssey Therapeutics, Inc.(ODTX): Biotech Combating Ulcerative Colitis, or UC, Files for IPO
- Biotech seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases filed its IPO on January 18th
- Lead program, OD-07656, is currently in a Phase 2a monotherapy trial for ulcerative colitis
- Potential IPO for Odyssey Therapeutics would be the first half of February
ACHV: Long-Term Exposure Requirement Complete
- Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.
- Topline results from ORCA-2 were reported in April 2022 and for ORCA-3 in May 2023.
- Results exceeded expectations on safety & efficacy parameters.
CCLD: Initiating Coverage of a Differentiated Technology-Led Business Solutions Provider Focused on the Healthcare Industry
- CareCloud, Inc. (NASDAQ: CCLD) is a technology company providing key business solutions to healthcare providers including small practices, large physician groups, and hospitals across the U.S. The company’s platform includes Revenue Cycle Management (RCM), Electronic Health Records (EHR), Practice Management (PM), digital health, and other healthcare business solutions.
- As of September 30, 2024, CCLD serviced approximately 40,000 providers across ~2,600 medical practices and hospitals.
- The company was founded in 2000 and is headquartered in New Jersey.
EVAX: Share Ratio Adjustment
- EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.
- The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology.
- The company changed the ADS ratio from 1 ADS representing 10 ordinary shares to 1 ADS from 50 ordinary shares.
SCLX: 3Q Earnings Beat Estimates
- SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.
- The company already has commercialized products that are proven to improve patients’ lives.
- The company announced 3Q2024 earnings that exceeded expectations and continues to look to grow revenues and its portfolio.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
